Search details
1.
Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage.
Circulation
; 146(23): 1758-1778, 2022 12 06.
Article
in English
| MEDLINE | ID: mdl-36259389
2.
Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis.
Biol Reprod
; 94(5): 110, 2016 05.
Article
in English
| MEDLINE | ID: mdl-27009040
3.
Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms.
Proc Natl Acad Sci U S A
; 110(49): 19778-83, 2013 Dec 03.
Article
in English
| MEDLINE | ID: mdl-24248367
4.
Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current.
Circ Res
; 109(9): 1024-1030, 2011 Oct 14.
Article
in English
| MEDLINE | ID: mdl-21903937
5.
Conserved expression and functions of PDE4 in rodent and human heart.
Basic Res Cardiol
; 106(2): 249-62, 2011 Mar.
Article
in English
| MEDLINE | ID: mdl-21161247
6.
Phosphodiesterase inhibition in heart failure.
Handb Exp Pharmacol
; (204): 237-49, 2011.
Article
in English
| MEDLINE | ID: mdl-21695643
7.
cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium.
J Pharmacol Exp Ther
; 330(3): 884-91, 2009 Sep.
Article
in English
| MEDLINE | ID: mdl-19546307
8.
Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.
J Card Fail
; 15(1): 31-4, 2009 Feb.
Article
in English
| MEDLINE | ID: mdl-19181291
9.
cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology.
Circ Res
; 100(11): 1569-78, 2007 Jun 08.
Article
in English
| MEDLINE | ID: mdl-17556670
10.
Multiple cAMP Phosphodiesterases Act Together to Prevent Premature Oocyte Meiosis and Ovulation.
Endocrinology
; 159(5): 2142-2152, 2018 05 01.
Article
in English
| MEDLINE | ID: mdl-29608743
11.
Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy.
Cardiovasc Res
; 62(3): 450-9, 2004 Jun 01.
Article
in English
| MEDLINE | ID: mdl-15158137
12.
Clinical effects of phosphodiesterase 3A mutations in inherited hypertension with brachydactyly.
Hypertension
; 66(4): 800-8, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26283042
13.
PDE3A mutations cause autosomal dominant hypertension with brachydactyly.
Nat Genet
; 47(6): 647-53, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25961942
14.
Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy.
Expert Opin Investig Drugs
; 11(11): 1529-36, 2002 Nov.
Article
in English
| MEDLINE | ID: mdl-12437500
15.
The academic paradigm is the problem.
J Investig Med
; 57(5): 632-3, 2009 Jun.
Article
in English
| MEDLINE | ID: mdl-19289971
16.
Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte.
Development
; 136(11): 1869-78, 2009 Jun.
Article
in English
| MEDLINE | ID: mdl-19429786
17.
Outcome of noncardiac surgery in patients with ventricular assist devices.
Am J Cardiol
; 103(5): 709-12, 2009 Mar 01.
Article
in English
| MEDLINE | ID: mdl-19231338
18.
Utility of virtual crossmatch in sensitized patients awaiting heart transplantation.
J Heart Lung Transplant
; 28(11): 1129-34, 2009 Nov.
Article
in English
| MEDLINE | ID: mdl-19782589
19.
Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes.
J Biol Chem
; 282(45): 32749-57, 2007 Nov 09.
Article
in English
| MEDLINE | ID: mdl-17726023
20.
Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
Expert Opin Investig Drugs
; 15(7): 733-42, 2006 Jul.
Article
in English
| MEDLINE | ID: mdl-16787138